Assistance Publique-hopitaux De Paris

Institut National De La Sante Et De La Recherche Medicale

Sorbonne Université

Centre National De La Recherche Scientifique

Université Pierre Et Marie Curie (paris 6)

Institut National De La Recherche Agronomique (inra)

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

Institut National De La Recherche Agronomique

Université De Nantes

Assistance Publique - Hopitaux De Paris (aphp)

Université D'angers

Institut National De La Sante Et De La Recherche Medicale (inserm)

Ecole D'ingenieurs De Purpan

Compagnie Gervais Danone

Université Pierre Et Marie Curie

Harry Sokol

Philippe Langella

Francine Jotereau

Johan Van Hylckama Vlieg

Luis Bermudez Humaran

Rebeca Martin Rosique

Florian Chain

Mathias Lavie-Richard

Marie-Laure Michel

Bruno Michel Lamas

Luis G Bermudez-Humaran

Vassilia Theodorou

Muriel Thomas

Germain Trugnan

Jean-Marc Chatel

Emmanuelle Godefroy

Jane Mea Natividad

Guillaume Sarrabayrouse

Frédéric Altare

Sylvie Miquel

Frédéric Carvalho

Henri Duboc

Philippe Seksik

Benedicte Pigneur-Arnaud

Elodie Quevrain

Christophe Michon

Marie-Anne Maubert

Mohamad Mohty

Patrick Veiga

Mathias Richard

Jane Natividad

Bénédicte Pigneur-Arnaud

Langella Philippe

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4CD8ααphenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of-specific cells among CD4CD8ααT lymphocytes, from a blood sample and without needing to assess theirspecificity. T lymphocytes with a CD4CD8ααCCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease ofis particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

Diagnosis, prognosis and treatment of a disease related to a decrease of

The present invention relates to a bacterial strain of thespecies selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.

strains for treating and preventing gastrointestinal pain

The present invention relates to the preventive or curative treatment of metabolic syndrome and the associated disorders with AhR agonist or microorganism producing AhR agonist.

Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders

A method for preventing or treating an inflammatory disease, such as inflammatory bowel disease and Crohn disease, is presented. The method includes administering to a patient a polypeptide having the amino acid sequence of SEQ ID NO: 1, a conservative derivative or a fragment thereof, a nucleic acid sequence encoding said polypeptide, a vector comprising said nucleic acid sequence or a host cell that has been transfected, infected or transformed by said nucleic acid sequence and/or by said vector.

Anti-inflammatory peptides and methods for treating inflammatory diseases

The invention relates to a bacterial strain of speciesdeposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.

strain CNCM 1-4573 for the treatment and prevention of gastrointestinal inflammation

The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.

Pharmaceutical compositions for preventing or treating inflammatory bowel diseases

Growing community of inventors

Paris, France

Harry Sokol